Silibinin exerts antidepressant effects by improving neurogenesis through BDNF/TrkB pathway. 2018

Yan-Jiao Li, and Yu-Jiao Li, and Liu-Di Yang, and Kun Zhang, and Kai-Yin Zheng, and Xin-Miao Wei, and Qi Yang, and Wen-Min Niu, and Ming-Gao Zhao, and Yu-Mei Wu
Precision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, 710038, PR China; Department of Pharmacology, School of Pharmacy, the Fourth Military Medical University, Xi'an, Shaanxi Province, 710032, PR China; Department of Acupuncture-moxibustion-massage, Shaanxi University of Chinese Medicine, Xi'an, Shaanxi Province, 712000, PR China.

Classic antidepressants benefit depression patients partially by improving neurogenesis and/or brain-derived neurotrophic factor (BDNF)/TrkB pathway which were impaired in depression. In this study, we demonstrated that Silibinin (SLB), a polyphenolic flavanoid from Silybum marianum, ameliorated reserpinized mouse depressant-like behaviors. The antidepressants of SLB administration was associated with increased neural stem cells (NSCs) proliferation and further confirmed in BDNF/TrkB signaling transduction. SLB treatment reversed the decreased expression levels of BDNF and its receptor TrkB, and the reduced activation of downstream target proteins including phosphorylated extracellular-regulated protein kinase (p-ERK) and phosphorylated cAMP-response element binding protein (p-CREB) in depressived hippocampus. Furthermore, intracerebroventricular injection of GNF5837, a TrkB antagonist, abrogated antidepressant-like effects of SLB in mice along with the improved NSC proliferation, as well as enhanced levels of p-ERK and p-CREB in mice hippocampus. Taken together, these results suggest that SLB may exert antidepressant effects through BDNF/TrkB signaling pathway to improve NSC proliferation in acute depression.

UI MeSH Term Description Entries
D008297 Male Males
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000077385 Silybin The major active component of silymarin flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum; it is used in the treatment of HEPATITIS; LIVER CIRRHOSIS; and CHEMICAL AND DRUG INDUCED LIVER INJURY, and has antineoplastic activity; silybins A and B are diastereomers. 2,3-Dehydrosilybin,Alepa-forte,Ardeyhepan,Cefasilymarin,Durasilymarin,Hepa-Merz Sil,Hepa-loges,HepaBesch,Hepar-Pasc,Heparsyx,Heplant,Lagosa,Legalon Forte,Silibin,Silibinin,Silibinin A,Silibinin B,Silybin A,Silybin B,Silybinin,2,3 Dehydrosilybin,Alepa forte,Hepa Merz Sil,Hepa loges,Hepar Pasc
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Yan-Jiao Li, and Yu-Jiao Li, and Liu-Di Yang, and Kun Zhang, and Kai-Yin Zheng, and Xin-Miao Wei, and Qi Yang, and Wen-Min Niu, and Ming-Gao Zhao, and Yu-Mei Wu
April 2024, Behavioural brain research,
Yan-Jiao Li, and Yu-Jiao Li, and Liu-Di Yang, and Kun Zhang, and Kai-Yin Zheng, and Xin-Miao Wei, and Qi Yang, and Wen-Min Niu, and Ming-Gao Zhao, and Yu-Mei Wu
June 2021, Journal of dairy science,
Yan-Jiao Li, and Yu-Jiao Li, and Liu-Di Yang, and Kun Zhang, and Kai-Yin Zheng, and Xin-Miao Wei, and Qi Yang, and Wen-Min Niu, and Ming-Gao Zhao, and Yu-Mei Wu
January 2019, Frontiers in pharmacology,
Yan-Jiao Li, and Yu-Jiao Li, and Liu-Di Yang, and Kun Zhang, and Kai-Yin Zheng, and Xin-Miao Wei, and Qi Yang, and Wen-Min Niu, and Ming-Gao Zhao, and Yu-Mei Wu
December 2014, The international journal of neuropsychopharmacology,
Yan-Jiao Li, and Yu-Jiao Li, and Liu-Di Yang, and Kun Zhang, and Kai-Yin Zheng, and Xin-Miao Wei, and Qi Yang, and Wen-Min Niu, and Ming-Gao Zhao, and Yu-Mei Wu
January 2024, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Yan-Jiao Li, and Yu-Jiao Li, and Liu-Di Yang, and Kun Zhang, and Kai-Yin Zheng, and Xin-Miao Wei, and Qi Yang, and Wen-Min Niu, and Ming-Gao Zhao, and Yu-Mei Wu
August 2021, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Yan-Jiao Li, and Yu-Jiao Li, and Liu-Di Yang, and Kun Zhang, and Kai-Yin Zheng, and Xin-Miao Wei, and Qi Yang, and Wen-Min Niu, and Ming-Gao Zhao, and Yu-Mei Wu
April 2023, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Yan-Jiao Li, and Yu-Jiao Li, and Liu-Di Yang, and Kun Zhang, and Kai-Yin Zheng, and Xin-Miao Wei, and Qi Yang, and Wen-Min Niu, and Ming-Gao Zhao, and Yu-Mei Wu
April 2018, Neurobiology of aging,
Yan-Jiao Li, and Yu-Jiao Li, and Liu-Di Yang, and Kun Zhang, and Kai-Yin Zheng, and Xin-Miao Wei, and Qi Yang, and Wen-Min Niu, and Ming-Gao Zhao, and Yu-Mei Wu
January 2021, Frontiers in pharmacology,
Yan-Jiao Li, and Yu-Jiao Li, and Liu-Di Yang, and Kun Zhang, and Kai-Yin Zheng, and Xin-Miao Wei, and Qi Yang, and Wen-Min Niu, and Ming-Gao Zhao, and Yu-Mei Wu
November 2019, Psychopharmacology,
Copied contents to your clipboard!